Antithrombotic Therapy for Inferior Vena Cava Stenting of Malignant Inferior Vena Cava Syndrome: A Questionnaire Study of Japan Interventional Radiology Study Group (JIVROSG)

Abstract

Purpose The aim of this study was to evaluate the differences in antithrombotic therapy policies for inferior vena cava (IVC) stent placement among institutions and interventional radiologists in Japan.

Materials and Methods The cross-sectional online-based questionnaire was conducted between December 2022 and January 2023, and a total of 114 institutions were included in this study. The questionnaire contained eight questions that were grouped into three sections: (1) whether IVC stents have been performed or not, (2) the number of IVC stent placements, and (3) the basic strategy of antithrombotic therapy for pre-, intra-, and post-IVC stent placement.

Results Of the 114 institutions, 38 responses (33%) were collected. Twenty-four of the 38 institutions (63%) had performed IVC stent placement during the study period. The mean number of IVC stent placements during the study period was 3.4 cases per institution. The most frequently selected antithrombotic therapeutic strategies pre-, intra-, and post-stenting were no antithrombotic therapy (62.5%), anticoagulation therapy (54.2%), and no antithrombotic therapy (41.7%).

Conclusion This study has revealed there is no consensus regarding antithrombotic therapy for IVC stent placement in Japan. The results of this study may contribute to our understanding of the status of antithrombotic therapy for IVC stent placement. Future prospective studies are warranted to clarify the periprocedural antithrombotic therapy for IVC stent placement.

Keywords

malignant IVC syndrome - inferior vena cava stent - anticoagulation therapy

Ethical Approval Statement

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required. This retrospective study was approved by the Institutional Ethics Committee (approval number: NCCH-2018–049).

Data Availability Statement

All the data published within this article will be made available by the corresponding author, upon reasonable request. We take full responsibility for the data, analyses, interpretation, and research conduct. We have full access to all data and have obtained the rights to publish these results.

Authors' Contribution

All authors made substantial contributions to the study concept or the data analysis or interpretation, drafted the manuscript or revised it critically for important intellectual content, approved the final version of the manuscript to be published, and agreed to be accountable for all aspects of the work.

Publication History

Article published online:
19 April 2024

• References

• 1 Brountzos EN, Binkert CA, Panagiotou IE, Petersen BD, Timmermans H, Lakin PC. Clinical outcome after intrahepatic venous stent placement for malignant inferior vena cava syndrome. Cardiovasc Intervent Radiol 2004; 27 (02) 129-136
• 2 Kuetting D, Thomas D, Wilhelm K, Pieper CC, Schild HH, Meyer C. Endovascular management of malignant inferior vena cava syndromes. Cardiovasc Intervent Radiol 2017; 40 (12) 1873-1881
• 3 Tanigawa N, Sawada S, Mishima K. et al. Clinical outcome of stenting in superior vena cava syndrome associated with malignant tumors. Comparison with conventional treatment. Acta Radiol 1998; 39 (06) 669-674
• 4 Takeuchi Y, Arai Y, Sone M. et al. Evaluation of stent placement for vena cava syndrome: phase II trial and phase III randomized controlled trial. Support Care Cancer 2019; 27 (03) 1081-1088
• 5 Sato Y, Inaba Y, Yamaura H, Takaki H, Arai Y. Malignant inferior vena cava syndrome and congestive hepatic failure treated by venous stent placement. J Vasc Interv Radiol 2012; 23 (10) 1377-1380
• 6 Oudkerk M, Heystraten FMJ, Stoter G. Stenting in malignant vena caval obstruction. Cancer 1993; 71 (01) 142-146
• 7 Levine GN, Bates ER, Bittl JA. et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 2016; 134 (10) e123-e155
• 8 Valgimigli M, Bueno H, Byrne RA. et al; ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39 (03) 213-260
• 9 Ozawa M, Sone M, Sugawara S. et al. Necessity of prophylactic anticoagulation therapy following inferior vena cava stent placement in patients with cancer. Interv Radiol (Higashimatsuyama) 2023; 8 (2) 70-74
• 10 Arendt VA, Mabud TS, Kuo WT. et al. Comparison of anticoagulation regimens following stent placement for nonthrombotic lower extremity venous disease. J Vasc Interv Radiol 2021; 32 (11) 1584-1590